Skip to main content

Advertisement

SpringerLink
Log in

Navigating Risk Stratification Systems for the Management of Patients With GIST

  • Bone and Soft Tissue Sarcomas
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

The central drivers of the aberrant behavior of gastrointestinal stromal tumors (GIST) are constitutively activated forms of stem-cell receptor factor, and, to a lesser extent, platelet-derived growth factor receptor alpha. Standard treatment for primary, localized GIST is surgical resection. Risk stratification systems assist in determining the risk of disease recurrence in individual patients with GIST, so disease management can be personalized.

Methods

In May 2010, a literature review of the PubMed database was conducted to identify articles pertaining to prognostic factors and risk stratification systems for GIST. Key results from these studies were analyzed.

Results

The first widely accepted risk stratification system for GIST, the National Institutes of Health consensus classification system, stratified patients into risk groups on the basis of tumor size and mitotic index. Tumor location (i.e., stomach or intestine) was subsequently shown to have independent prognostic value and was incorporated into the Miettinen-Lasota/Armed Forces Institute of Pathology risk stratification system. Tumor size, location, and mitotic index remain the main variables used in risk stratification systems. Other variables such as tumor rupture and GIST genotype have recently been shown to have prognostic value. As an alternative to stratification into discrete groups, nomograms present risk of recurrence as percentages on a continuous scale. Improved use of existing prognostic variables and routine incorporation of additional variables (e.g., GIST genotype) will further refine risk stratification systems.

Conclusions

Refinement of risk stratification systems will increase the precision of these systems for predicting recurrence, which may facilitate improvements in individual disease management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51–8.

    Article  PubMed  CAS  Google Scholar 

  2. Joensuu H, Fletcher C, Dimitrijevic S, et al. Management of malignant gastrointestinal stromal tumours. Lancet Oncol. 2002;3:655–64.

    Article  PubMed  CAS  Google Scholar 

  3. Perez EA, Livingstone AS, Franceschi D, et al. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. J Am Coll Surg. 2006;202:623–9.

    Article  PubMed  Google Scholar 

  4. Hassan I, You YN, Shyyan R, et al. Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis. Ann Surg Oncol. 2008;15:52–9.

    Article  PubMed  Google Scholar 

  5. Lin SC, Huang MJ, Zeng CY, et al. Clinical manifestations and prognostic factors in patients with gastrointestinal stromal tumors. World J Gastroenterol. 2003;9:2809–12.

    PubMed  Google Scholar 

  6. Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era—a population-based study in western Sweden. Cancer. 2005;103:821–9.

    Article  PubMed  Google Scholar 

  7. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33:459–65.

    Article  PubMed  Google Scholar 

  8. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol. 2005;29:52–68.

    Article  PubMed  Google Scholar 

  9. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006;130:1466–78.

    PubMed  CAS  Google Scholar 

  10. Miettinen M, Makhlouf H, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol. 2006;30:477–89.

    Article  PubMed  Google Scholar 

  11. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004;22:3813–25.

    Article  PubMed  CAS  Google Scholar 

  12. Corless CL, Heinrich MC. Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol. 2008;3:557–86.

    Article  PubMed  CAS  Google Scholar 

  13. Heinrich MC, Rubin BP, Longley BJ, Fletcher JA. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol. 2002;33:484–95.

    Article  PubMed  CAS  Google Scholar 

  14. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4342–9.

    Article  PubMed  CAS  Google Scholar 

  15. Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology. 2003;125:660–7.

    Article  PubMed  CAS  Google Scholar 

  16. Martin J, Poveda A, Llombart-Bosch A, et al. Deletions affecting codons 557–558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J Clin Oncol. 2005;23:6190–8.

    Article  PubMed  CAS  Google Scholar 

  17. Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol. 2008;26:5360–7.

    Article  PubMed  CAS  Google Scholar 

  18. Corless CL, Ballman KV, Antonescu C, et al. Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): results of the intergroup phase III trial ACOSOG Z9001 (abstract). J Clin Oncol. 2010;28(15 suppl):10006.

    Google Scholar 

  19. DeMatteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:1097–104.

    Article  PubMed  CAS  Google Scholar 

  20. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008;39:1411–9.

    Article  PubMed  Google Scholar 

  21. Huang HY, Li CF, Huang WW, et al. A modification of NIH consensus criteria to better distinguish the highly lethal subset of primary localized gastrointestinal stromal tumors: a subdivision of the original high-risk group on the basis of outcome. Surgery. 2007;141:748–56.

    Article  PubMed  Google Scholar 

  22. Mucciarini C, Rossi G, Bertolini F, et al. Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. BMC Cancer. 2007;7:230.

    Article  PubMed  Google Scholar 

  23. Rutkowski P, Nowecki ZI, Michej W, et al. Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Ann Surg Oncol. 2007;14:2018–27.

    Article  PubMed  Google Scholar 

  24. Takahashi T, Nakajima K, Nishitani A, et al. An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors. Int J Clin Oncol. 2007;12:369–74.

    Article  PubMed  CAS  Google Scholar 

  25. DeMatteo RP, Gold JS, Saran L, et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer. 2008;112:608–15.

    Article  PubMed  Google Scholar 

  26. Goh BK, Chow PK, Yap WM, et al. Which is the optimal risk stratification system for surgically treated localized primary GIST? Comparison of three contemporary prognostic criteria in 171 tumors and a proposal for a modified Armed Forces Institute of Pathology risk criteria. Ann Surg Oncol. 2008;15:2153–63.

    Article  PubMed  Google Scholar 

  27. Rutkowski P, Bylina E, Wozniak A, et al. Validation of Joensuu risk criteria for primary resectable gastrointestinal stromal tumors (abstract). J Clin Oncol. 2010;28(15 suppl):10018.

    Google Scholar 

  28. Casali PG, Blay JY. Gastrointestinal stromal tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(suppl 5):v98–102.

    Article  PubMed  Google Scholar 

  29. Dei Tos AP, Rossi S, Messerini L, et al. The natural history of imatinib-naive GIST: a retrospective analysis of 929 cases with long-term follow-up (abstract). J Clin Oncol. 2009;27(15 suppl):10555.

    Google Scholar 

  30. Gold JS, Gonen M, Gutierrez A, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol. 2009;10:1045–52.

    Article  PubMed  Google Scholar 

  31. European Medicines Agency. 2010. Glivec. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000406/human_med_000808.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124. Accessed September 2, 2010.

  32. Cohen MH, Cortazar P, Justice R, Pazdur R. Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumors. Oncologist. 2010;15:300–7.

    Article  PubMed  CAS  Google Scholar 

  33. Clinical practice guidelines in oncology. Soft tissue sarcoma. V.2.2010. http://www.nccn.org/professionals/physician_gls/PDF/sarcoma.pdf. Accessed September 2, 2010.

  34. Ahmed I, Welch NT, Parsons SL. Gastrointestinal stromal tumours (GIST)—17 years experience from Mid Trent Region (United Kingdom). Eur J Surg Oncol. 2008;34:445–9.

    PubMed  CAS  Google Scholar 

  35. Nilsson B, Sjolund K, Kindblom LG, et al. Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST). Br J Cancer. 2007;96:1656–8.

    Article  PubMed  CAS  Google Scholar 

  36. Martin-Broto J, Gutierrez A, Garcia-del-Muro X, et al. Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study. Ann Oncol. 2010;21:1552–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals. I thank Robert Gillespie, PhD, for his medical editorial assistance.

Conflict of interest

The author has received prior honoraria from Novartis, but no compensation was provided for this article.

Author information

Authors and Affiliations

  1. Department of Sarcoma Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

    Shreyaskumar Patel MD

Authors
  1. Shreyaskumar Patel MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shreyaskumar Patel MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Patel, S. Navigating Risk Stratification Systems for the Management of Patients With GIST. Ann Surg Oncol 18, 1698–1704 (2011). https://doi.org/10.1245/s10434-010-1496-z

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-010-1496-z

Keywords

Search

Navigation